Acelyrin Management

Management criteria checks 0/4

Acelyrin's CEO is Mina Kim, appointed in May 2024, has a tenure of less than a year. directly owns 0.025% of the company’s shares, worth $107.08K. The average tenure of the management team and the board of directors is 1.1 years and 2.2 years respectively.

Key information

Mina Kim

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.02%
Management average tenure	1.1yrs
Board average tenure	2.2yrs

Recent management updates

Recent updates

CEO

Mina Kim (50 yo)

less than a year

Tenure

Ms. Mina Kim joined and served as a Chief Legal Officer at Zymergen, Inc. since January 2020 until August 2022 and also serves as its Corporate Secretary. She served as the Chief Legal and Administrative O...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mina Kim	CEO & Director	less than a year	no data	0.025% $ 116.2k
Gilbert Labrucherie	CFO & Chief Business Officer	1.2yrs	no data	0.047% $ 221.0k
Tyler Marciniak	Head of Investor Relations & Communications	2.5yrs	no data	no data
K. Murugan	Chief Legal Officer	no data	no data	no data
Kelly Chow	Chief People Officer	no data	no data	no data
Suzy Buckhalter	Senior Director of Finance & Accounting	no data	no data	no data
Kenneth Lock	Chief Commercial Officer	1.3yrs	no data	no data
Shephard Mpofu	Chief Medical Officer	1.1yrs	no data	no data
Patricia Turney	Chief Technical Operations Officer	less than a year	no data	no data

1.1yrs

Average Tenure

50yo

Average Age

Experienced Management: SLRN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Mina Kim	CEO & Director	less than a year	no data	0.025% $ 116.2k
Bruce Cozadd	Independent Chairman	2.7yrs	US$390.49k	0% $ 0
Beth Seidenberg	Independent Director	4.1yrs	US$349.51k	0.060% $ 282.0k
Lynn Tetrault	Independent Director	less than a year	US$482.26k	0% $ 0
C. Machado	Independent Director	3.6yrs	US$402.20k	0.015% $ 69.0k
Alan Colowick	Independent Director	3yrs	no data	no data
Dawn Svoronos	Independent Director	1.9yrs	US$376.67k	0.015% $ 70.5k
Daniel Becker	Independent Director	2.2yrs	US$351.09k	0.0030% $ 14.1k
Henry Gosebruch	Independent Director	1.7yrs	US$1.02m	0.050% $ 235.0k

2.2yrs

Average Tenure

60yo

Average Age

Experienced Board: SLRN's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Acelyrin Management

Management criteria checks 0/4

Key information

Recent management updates

Acelyrin, Inc. Announces CEO Changes

Acelyrin, Inc., Annual General Meeting, Jun 07, 2024

Chief Medical Officer notifies of intention to sell stock

Co-Founder recently sold US$119k worth of stock

Acelyrin, Inc. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

High number of new and inexperienced directors

Recent updates

Acelyrin, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Acelyrin, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch

New minor risk - Shareholder dilution

Price target decreased by 47% to US$12.00

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa

Acelyrin, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Companies Like Acelyrin (NASDAQ:SLRN) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024

New major risk - Revenue and earnings growth

Price target decreased by 8.3% to US$22.17

Acelyrin, Inc. Announces CEO Changes

Acelyrin, Inc. to Report Q1, 2024 Results on May 13, 2024

Acelyrin, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-Of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis

Acelyrin, Inc. Announces Long-Term 32-Week Data from the Phase 2B Trial of Izokibep in Hidradenitis Suppurativa

New minor risk - Insider selling

Co-Founder recently sold US$119k worth of stock

Acelyrin, Inc. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

High number of new and inexperienced directors

Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Acelyrin, Inc

Acelyrin, Inc. Appoints Lynn Tetrault to Board of Directors

Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program

Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program

Equity Alert: Rosen Encourages Acelyrin, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Equity Alert: Rosen Encourages Acelyrin, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Acelyrin, Inc. Appoints Patricia Turney as Chief Technical Operations Officer

Acelyrin, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Financial data availability

Acelyrin, Inc. Appoints Shephard Mpofu as Senior Vice President of Development

Acelyrin, Inc. Appoints Gil Labrucherie as Full Time Chief Financial Officer

New major risk - Revenue and earnings growth

ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer

New major risk - Financial position

Acelyrin, Inc. has completed an IPO in the amount of $540 million.

No independent directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age